Compact but mighty: Biology and applications of type III-E CRISPR-Cas systems
- PMID: 36459983
- DOI: 10.1016/j.molcel.2022.11.007
Compact but mighty: Biology and applications of type III-E CRISPR-Cas systems
Abstract
In this issue, Liu et al. present an in-depth study aiming to unravel the structural, biochemical, and physiological aspects of how type III-E CRISPR-Cas systems trigger abortive infection by activating a protease upon target RNA recognition.1.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests J.A.S. is a founder and shareholder of Scope Biosciences B.V. J.v.d.O. and R.H.J.S. are shareholders and members of the scientific board of Scope Biosciences B.V. J.v.d.O. is a scientific advisor of NTrans Technologies and Hudson River Biotechnology. J.A.S., J.v.d.O., and R.H.J.S. are inventors on CRISPR-Cas related patents/patent applications.
Comment on
-
Target RNA activates the protease activity of Craspase to confer antiviral defense.Mol Cell. 2022 Dec 1;82(23):4503-4518.e8. doi: 10.1016/j.molcel.2022.10.007. Epub 2022 Oct 27. Mol Cell. 2022. PMID: 36306795
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
